HomeCompareHARP vs MO

HARP vs MO: Dividend Comparison 2026

HARP yields 8.69% · MO yields 6.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MO wins by $42.1K in total portfolio value· pulled ahead in Year 7
10 years
HARP
HARP
● Live price
8.69%
Share price
$23.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.6K
Annual income
$1,504.59
Full HARP calculator →
MO
Altria Group Inc.
● Live price
6.27%
Share price
$67.02
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$28,968.54
Full MO calculator →

Portfolio growth — HARP vs MO

📍 MO pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHARPMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HARP + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HARP pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HARP
Annual income on $10K today (after 15% tax)
$738.81/yr
After 10yr DRIP, annual income (after tax)
$1,278.90/yr
MO
Annual income on $10K today (after 15% tax)
$532.68/yr
After 10yr DRIP, annual income (after tax)
$24,623.26/yr
At 15% tax rate, MO beats the other by $23,344.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HARP + MO for your $10,000?

HARP: 50%MO: 50%
100% MO50/50100% HARP
Portfolio after 10yr
$56.6K
Annual income
$15,236.56/yr
Blended yield
26.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

HARP
Analyst Ratings
7
Buy
2
Hold
Consensus: Buy
Price Target
$700.00
+2942.2% upside vs current
Range: $700.00 — $700.00
Altman Z
0.4
Piotroski
2/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-8.6% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HARP buys
0
MO buys
0
No recent congressional trades found for HARP or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHARPMO
Forward yield8.69%6.27%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$35.6K$77.7K
Annual income after 10y$1,504.59$28,968.54
Total dividends collected$11.9K$72.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$700.00$61.25

Year-by-year: HARP vs MO ($10,000, DRIP)

YearHARP PortfolioHARP Income/yrMO PortfolioMO Income/yrGap
1$11,569$869.19$10,558$768.31+$1.0KHARP
2$13,319$939.79$11,352$1,015.87+$2.0KHARP
3$15,262$1,011.14$12,482$1,367.86+$2.8KHARP
4$17,414$1,082.88$14,103$1,883.39+$3.3KHARP
5$19,787$1,154.69$16,472$2,664.91+$3.3KHARP
6$22,399$1,226.25$20,024$3,897.79+$2.4KHARP
7← crossover$25,264$1,297.27$25,537$5,933.74$273.00MO
8$28,400$1,367.49$34,478$9,476.77$6.1KMO
9$31,824$1,436.67$49,776$16,022.63$18.0KMO
10$35,557$1,504.59$77,699$28,968.54$42.1KMO

HARP vs MO: Complete Analysis 2026

HARPStock

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Full HARP Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this HARP vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HARP vs SCHDHARP vs JEPIHARP vs OHARP vs KOHARP vs MAINHARP vs PMHARP vs BTIHARP vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.